

Cost-Effectiveness Analysis Of Follow-Up Strategies For Localised Or Locally Advanced Renal Cell Carcinoma From The UK NHS Perspective

Yuanyuan Zhang, Hannah Tebbs, Lindsay Claxton

National Institute for Health and Care Excellence, UK

Background

There is no clinical consensus or clear evidence on the optimal follow-up strategy for people who have completed treatment for localised or locally advanced renal cell carcinoma (RCC). Follow-up is crucial for early detection of disease recurrence and the evaluation of long-term sequelae. Tumours detected earlier are more likely to be asymptomatic and have a better prognosis than symptomatic ones. Evidence from the multinational RECUR study, including UK participants, suggests that increased imaging scans during follow up could not demonstrate a survival benefit for the overall population. This study explored the cost-effectiveness of a range of follow-up strategies for groups at low, intermediate and high risk of progression.


Methods

A lifetime semi-Markov model was developed in R to compare the cost effectiveness of two follow-up strategies for people who have undergone nephrectomy. The strategies compared were high proportion versus a low proportion of cross-sectional imaging strategy ("low CSI" and "high CSI"), and a low versus a high imaging frequency strategy ("low IF" and "high IF").

The population was stratified by recurrence risk: low, intermediate and high. Recurrence rates, survival following recurrence and probability of detecting recurrence were derived from the RECUR study^{1,2,3}. Parametric models were fitted to the Kaplan-Meier curves to extrapolate long-term recurrence and survival outcomes.

Resource use, costs and utility values were sourced from published literature reviews, NICE technology appraisals and national sources.

Figure 1: Economic model diagram



Patient flow and assumptions

- The risk of a detected recurrence being symptomatic or non-symptomatic depends on the follow-up strategies and risk group.
- The probability of a recurrence being symptomatic was assumed to be constant over time and constant between PI and PC recurrences.
- Detecting recurrences while asymptomatic leads to better OS than recurrences that are symptomatic when detected

Outcomes

High CSI and high IF strategies appear to be cost effective in the low- and intermediate-risk groups at a threshold of £20,000 per QALY. In the high-risk group, high CSI does not appear to be cost effective. The differences in outcomes (QALYs) were relatively small, with the majority of QALYs in the disease-free health state.

The probability that an imaging strategy detecting a recurrence being asymptomatic (compared to a symptomatic recurrence), the total cost of imaging, and the time to curable recurrence had the greatest influence on results.

Table 1: Probabilistic cost-utility results

Strategy	Total cost	Total QALYs	Inc. NMB*	ICER	Prob cost effective
Low-risk group					
Higher vs lower CSI					
<50% CSI	£1,801	12.81	NA	-	-
>50% CSI	£1,969	12.85	£498	£5,046	100%
Higher vs lower IF					
Low intensity	£1,484	12.81	NA	-	-
High intensity	£2,241	12.86	£265	£14,811	73%
Intermediate-risk group					
Higher vs lower CSI					
<50% CSI	£2,858	10.51	NA	-	-
>50% CSI	£3,127	10.59	£1,271	£3,490	99%
Higher vs lower IF					
Low intensity	£2,491	10.53	NA	-	-
High intensity	£3,441	10.61	£583	£12,398	85%
High-risk group					
Higher vs lower CSI					
<50% CSI	£2,915	9.01	NA	-	-
>50% CSI	£2,910	8.90	£2,183	Dom.	0%
Higher vs lower IF					
Low intensity	£2,479	8.91	NA	-	-
High intensity	£3,322	8.95	-£48	£21,208	47%

* Based on £20,000 per QALY

Figure 2: Sensitivity analysis: high CSI vs low CSI imaging strategy





Figure 3: Sensitivity analysis: high vs low intensity IF



Discussion

In the high-risk group, high CSI was not cost-effective while high IF remained uncertain. This was due to clinically implausible and counterintuitive findings from the RECUR study, such as more non-symptomatic recurrences detected in low CSI than high CSI. Any patterns in effectiveness across risk groups are likely to be due to the issues with the underlying effectiveness evidence rather than any actual difference in effectiveness.

Conclusions

The cost effectiveness results are subject to uncertainty due to limitations with the underlying clinical effectiveness data. Further research is warranted to establish the benefits of different risk-stratified imaging strategies.

- Dabestani, S., Beisland, C., Stewart, G. D., et al. (2019a). Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European urology focus, 5(5), 857-866. <https://doi.org/10.1016/j.euf.2018.02.010>
- Dabestani, S., Beisland, C., Stewart, G. D., et al. (2019b). Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). European urology, 75(2), 261-264. <https://doi.org/10.1016/j.euro.2018.10.007>
- Dabestani, S., Beisland, C., Stewart, G. D., et al. (2019c). Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scandinavian journal of urology, 53(1), 14-20. <https://doi.org/10.1080/21681805.2019.1588919>